

# **Remote Decentralised Clinical Trials**

Improving clinical trials' efficacy and effectiveness

Name of Project: Trials@Home

**Duration: 60 months** 

**Funded by: Innovative Medicines Initiative 2** 



## **Background & Objectives**

In a traditional setting, clinical trial participants must regularly visit a clinical trial centre for face-to-face evaluation.

This is not only **burdensome** for the participant, but also **potentially hinders the trials' recruitment process and lowers retention rates.** This leads to clinical trials being inefficient, expensive and sometimes invalid.

Remote Decentralised Clinical Trials (RDCTs) happen in a participant's home setting through digital tools and have the potential to remedy some of the traditional clinical trials' major constraints. They potentially also allow for broader participation.

If successful, RDCTs could make it easier to recruit and retain larger numbers of patients, including people from groups that are often under-represented in trials. Continuous data collection can also be more representative of the real world.

Diabetes is the chosen therapeutic area for this project.

# **IDF Europe's Role**

- Fraction of Represent the perspectives of people living with diabetes as an association and via representatives on the project's External Stakeholder Platform, across all aspects of the project.
- √ Participate in all communications and dissemination activities.

#### **Deliverables**

- A pan-EU pilot to compare traditional clinical trial approaches to full and hybrid RCDT approaches
- Recommendations on set up and feasibility of RDCTs including use of technology, available tools, ethical and regulatory frameworks
- Training kits for deploying pan-EU RCDTs for principal investigators, HCPs, patients, inspectors, pharmaceutical companies and clinical research organisations.
- Virtual education/information sessions for company providers/developers of technologies.

## **Expected Impact**

- Higher speed, quality and efficacy and lower overall costs of clinical trials
- More representative data sets and broader range of real world evidence
- Reduced trial burden, improved recruitment and retention rates
- Faster development of innovative treatment

For more information and a complete list of the project partners, please visit the project website: https://trialsathome.com/ or contact us:idfeurope@idf-europe.org

The research leading to these results has received support from the EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking (H2020-JTI-IMI2) Trials@Home grant n° 831458.





